PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

OxyContin maker Purdue Pharma launches campaign for opioid victims to file claims

Purdue Pharma, the drug company that makes OxyContin launched a $23.8 million ad campaign Monday alerting victims where to file claims if they have been affected or harmed by the opioid.

The company filed for bankruptcy in September as part of a tentative settlement in the case central to the country’s opioid crisis, and the ad campaign is part of a stipulation in similar cases that require the company to notify victims that they are able to file claims. In this case, the Stamford, Conn.-based company is looking at a proposed settlement that could be worth more than $10 billion over time, including the value of drugs it is producing. The settlement will also require the Sackler family, which owns the company, to give up control of the business while also contributing $3 billion over the next seven years and another $1.5 billion pending the sale of the family’s global pharmaceutical business, Mundipharma.

The ad campaign — which began online but is expected to appear in magazines, newspapers, TV and radio, billboards, movie theaters and other places — is expected to reach 95 percent of adults in America. Victims have until the end of June to file claims.

Although suits against Purdue have mostly been filed by government entities alleging that the company promoted its drugs to doctors by misleading and downplaying risks and overstating benefits, the ads allow users of the drug who may not necessarily identify themselves as victims to come forward and seek damages.

It remains to be seen who exactly would qualify for settlement money or how much they would receive. In addition, distinctions between payouts to illicit drug users who abused OxyContin versus people who were prescribed the drug and became addicted are subject to negotiations.

“A lot of the victims don’t know that they were victimized. They may think that they’re addicts. They may think that they have a moral failing or a character failing,” said Ed Neiger, a lawyer representing a committee of individuals seeking a say in the Purdue bankruptcy. “There were people in a boardroom that caused them to become addicted to opioids.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026